Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service breast reconstruction cases in Louisiana: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 17% on average (125 state-years, 2020–2024): small markets swing, so treat it as rough.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 2 | 291 | 42% |
| 2020 | 3 | 275 | 45% |
| 2021 | 6 | 278 | 51% |
| 2022 | 5 | 331 | 54% |
| 2023 | 5 | 340 | 58% |
| 2024 | 7 | 352 | 60% |
| 2025 from claims | – | 543 439–638 | 61% |
| 2026 forecast | – | 582 456–731 | 62% |
| 2027 forecast | – | 628 466–831 | 63% |
| 2028 forecast | – | 677 480–935 | 63% |
| 2029 forecast | – | 730 496–1,047 | 64% |
| 2030 forecast | – | 787 516–1,168 | 65% |
Implant- and flap-based reconstruction; ADM and expander call point. Professional codes (what the surgeon bills): CPT 19357, 19340, 19342, 19364, 19380.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 100% of the cases CMS names in Louisiana; 5 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 32% inpatient hospital, 68% hospital outpatient.
CMS rule changes ahead
From CMS’s OPPS/ASC final rules; the move measured on CMS’s claim summary, nationally, code by code. Medicare only, and not in the projected bars.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| Florida | 11 | 1,327−4.8%/yr | −4.8%/yr | 0.6 | 4% | 1,340 in 2030+0.2%/yr |
| Texas | 6 | 1,208−7.1%/yr | −7.1%/yr | 0.6 | 6% | 1,830 in 2030+7.1%/yr |
| Georgia | 1 | 590−6.3%/yr | −6.3%/yr | 0.7 | 0% | 900 in 2030+7.4%/yr |
| Maryland | 1 | 439−4.8%/yr | −4.8%/yr | 0.5 | 0% | 540 in 2030+3.5%/yr |
| Virginia | 3 | 428−9.4%/yr | −9.4%/yr | 0.4 | 0% | 410 in 2030−0.8%/yr |
| Tennessee | 3 | 337−11%/yr | −11%/yr | 0.5 | 6% | 470 in 2030+5.5%/yr |
| North Carolina | 0 | 327−13%/yr | −13%/yr | 0.3 | 0% | 330 in 2030−0.1%/yr |
| South Carolina | 1 | 295−3.4%/yr | −3.4%/yr | 0.4 | 0% | 360 in 2030+3.3%/yr |
| Kentucky | 1 | 152−5.7%/yr | −5.7%/yr | 0.3 | 0% | 110 in 2030−4.6%/yr |
| Mississippi | 0 | 123−12%/yr | −12%/yr | 0.3 | 58% | 90 in 2030−4.2%/yr |
| Arkansas | 0 | 111−8.5%/yr | −8.5%/yr | 0.3 | 0% | 50 in 2030−13%/yr |
| Oklahoma | 2 | 110−8.8%/yr | −8.8%/yr | 0.2 | 0% | 120 in 2030+1.2%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Hernia repair | 21 | 2,378−5.5%/yr | −5.5%/yr | 6.21.0× | 3% | 2,210 in 2030−1.2%/yr |
| Cholecystectomy & appendectomy | 56 | 2,158−8.2%/yr | −8.2%/yr | 5.41.2× | 3% | 2,120 in 2030−0.3%/yr |
| Colorectal resection | 3 | 766−7.5%/yr | −7.5%/yr | 1.91.1× | 0% | 690 in 2030−1.6%/yr |
| Antireflux & hiatal hernia surgery | 4 | 371−4.8%/yr | −4.8%/yr | 0.91.2× | 0% | 300 in 2030−3.6%/yr |
Breast reconstruction in every state, and its device makers · Every procedure market in Louisiana · Every state · Compare with Florida
Abbvie leads with 54% of company spending on these surgeons in 2025, level with 2024.
In 2025, 6 companies reported engagement with Louisiana’s surgeons worth $26K in consulting, speaking, meals and travel tied to these products, about $3,687 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 20 clearances and approvals in the category.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.